WaveMan
WaveMan · Company
ACTU · Actuate Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ACTU Actuate Therapeutics (ACTU) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001652935
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
35
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced

Actuate Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for ACTUATE THERAPEUTICS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
THOMSON TODD S
Director
SELL
2026-01-07 SECtraded 2026-01-05
280,000
$1.6M
-91.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 30.9% of the 904,795 shares held after it.
  • No other insider sold within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director THOMSON TODD S sold about $1.6M of ACTU on Jan 5, 2026, the largest insider sale at the company on our record; 35 funds added in the latest 13F quarter.
Bios Equity COF, LP
Director
BUY
2025-06-30 SECtraded 2025-06-27
71,428
$500.0K
-91.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 36.4% of the 196,428 shares held after it.
  • 2 other insiders bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bios Equity COF, LP bought about $500.0K of ACTU on Jun 27, 2025; 2 other insiders bought within 30 days and 35 funds added in the latest 13F quarter.
BIOS Fund II, LP
Director
BUY
2025-06-30 SECtraded 2025-06-27
71,428
$500.0K
-91.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 14, 2024.
  • The trade is 36.4% of the 196,428 shares held after it.
  • 2 other insiders bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BIOS Fund II, LP bought about $500.0K of ACTU on Jun 27, 2025; 2 other insiders bought within 30 days and 35 funds added in the latest 13F quarter.
BIOS Actuate Co-Invest I, LP
Director
BUY
2025-06-30 SECtraded 2025-06-27
71,428
$500.0K
-91.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 36.4% of the 196,428 shares held after it.
  • 2 other insiders bought within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BIOS Actuate Co-Invest I, LP bought about $500.0K of ACTU on Jun 27, 2025; 2 other insiders bought within 30 days and 35 funds added in the latest 13F quarter.
Bios Clinical Opportunity Fund, LP
Director
SELL
2024-08-20 SECtraded 2024-08-14
2,324
$18.6K
-93.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.8% of the 131,248 shares held after it.
  • 6 other insiders sold within 30 days.
  • 35 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bios Clinical Opportunity Fund, LP sold about $18.6K of ACTU on Aug 14, 2024, the largest insider sale at the company on our record; 6 other insiders sold within 30 days and 35 funds added in the latest 13F quarter.
29 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 24 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
35 funds bought in last quarter
below 60% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
15.5% of the float short (float per yahoo 2026-10-26) · 5.6 days to cover · settled 2026-09-30
more than 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ACTU

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-92.7%12M
-94%-61%-27%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-01-05 · THOMSON TODD S sold $1.6M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ACTU: institutional holders (13F)

13F holdings, latest reported quarter
BIOS Capital Management, LP
10,049,996 sh
$15.4M
Voss Capital, LP
1,725,000 sh
$2.6M
VANGUARD CAPITAL MANAGEMENT LLC
393,433 sh
$602.0K
Palogic Value Management, L.P.
200,000 sh
$306.0K
AQR CAPITAL MANAGEMENT LLC
127,493 sh
$195.1K

Congress trades in ACTU

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ACTU planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ACTU mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$35.9K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$58.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$2.6K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$17.9K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$11.1K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 INDEX FUND
$97.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 35 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ACTU financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-336.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$22.5M-$25.2M-$25.0M
Net income-$22.2M-$27.3M-$24.7M
EPS (diluted)-1.06-3.26-17.24
Operating cash flow-$19.2M-$21.8M-$21.6M
Cash$13.2M$8.6Mn/a
SEC XBRL, fiscal years, as known on 2026-10-27

ACTU Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
40
Inputs
  • Funds adding, latest quarter35 · 40 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
24
Inputs
  • Short interest, % of float+15.5% · 24 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies